EZH2 and diffuse large B-cell lymphoma: Positive results were obtained with Tazemetostat as a monotherapy in R/R DLBCL [92,93], and it appeared to be safe in combination with R-CHOP in elderly nd DLBCL patients (age 60–80) with or without EZH2 mutation [94].